X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (139) 139
rosuvastatin calcium (105) 105
rosuvastatin (104) 104
index medicus (90) 90
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (87) 87
male (87) 87
female (83) 83
fluorobenzenes - therapeutic use (69) 69
pyrimidines - therapeutic use (69) 69
sulfonamides - therapeutic use (69) 69
statins (67) 67
middle aged (65) 65
aged (64) 64
atorvastatin (60) 60
cholesterol (52) 52
hydroxymethylglutaryl-coa reductase inhibitors - economics (46) 46
adult (42) 42
fluorobenzenes - economics (39) 39
pyrimidines - economics (38) 38
sulfonamides - economics (38) 38
pravastatin (37) 37
cost-benefit analysis (34) 34
pharmacology & pharmacy (34) 34
treatment outcome (33) 33
atorvastatin calcium (32) 32
simvastatin - therapeutic use (31) 31
cardiovascular disease (30) 30
cholesterol, ldl - blood (30) 30
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (30) 30
hypercholesterolemia - drug therapy (30) 30
prevention (30) 30
medicine, general & internal (29) 29
risk factors (29) 29
cardiovascular diseases - prevention & control (28) 28
heptanoic acids - therapeutic use (28) 28
pyrroles - therapeutic use (28) 28
simvastatin (27) 27
antilipemic agents (26) 26
cardiac & cardiovascular systems (26) 26
risk (26) 26
analysis (25) 25
primary prevention (25) 25
coronary-heart-disease (24) 24
drug therapy (23) 23
fluorobenzenes - administration & dosage (22) 22
retrospective studies (21) 21
safety (21) 21
pyrimidines - administration & dosage (20) 20
sulfonamides - administration & dosage (20) 20
anticholesteremic agents - therapeutic use (19) 19
cardiovascular diseases (19) 19
cardiovascular-disease (19) 19
heptanoic acids - economics (19) 19
hypercholesterolemia (19) 19
metaanalysis (19) 19
pyrroles - economics (19) 19
randomized controlled trials as topic (19) 19
simvastatin - economics (19) 19
c-reactive protein (18) 18
efficacy (18) 18
lipids (18) 18
mortality (18) 18
therapy (18) 18
aged, 80 and over (17) 17
events (17) 17
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (17) 17
statin (17) 17
cost-effectiveness (16) 16
fluorobenzenes - adverse effects (16) 16
low density lipoproteins (16) 16
pyrimidines - adverse effects (16) 16
sulfonamides - adverse effects (16) 16
united states (16) 16
dosage and administration (15) 15
hypercholesterolemia - blood (15) 15
animals (14) 14
health care sciences & services (14) 14
medicine (14) 14
nutritional and metabolic diseases (14) 14
rosuvastatin calcium - therapeutic use (14) 14
studies (14) 14
anticholesteremic agents - economics (13) 13
clinical trials (13) 13
diabetes (13) 13
internal medicine (13) 13
research (13) 13
cholesterol, ldl - drug effects (12) 12
dose-response relationship, drug (12) 12
dyslipidemias - drug therapy (12) 12
medicine, research & experimental (12) 12
cardiovascular agents (11) 11
coronary heart disease (11) 11
fluorobenzenes - pharmacology (11) 11
hypercholesterolemia - economics (11) 11
pravastatin - therapeutic use (11) 11
pyrimidines - pharmacology (11) 11
sulfonamides - pharmacology (11) 11
cardiovascular diseases - drug therapy (10) 10
cardiovascular diseases - economics (10) 10
drugs, generic - economics (10) 10
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (170) 170
Dutch (2) 2
Spanish (2) 2
German (1) 1
Japanese (1) 1
Portuguese (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of General Internal Medicine, ISSN 0884-8734, 11/2015, Volume 30, Issue 11, pp. 1645 - 1650
Reducing patient cost-sharing and engaging patients in disease management activities have been shown to increase uptake of evidence-based care.To evaluate the... 
Medicine & Public Health | Internal Medicine | MEDICINE, GENERAL & INTERNAL | PROGRAMS | MEDICATION ADHERENCE | HEALTH CARE SCIENCES & SERVICES | Medication Adherence - statistics & numerical data | Metformin - therapeutic use | Rosuvastatin Calcium - therapeutic use | Hypoglycemic Agents - economics | United States | Humans | Middle Aged | Tetrazoles - economics | Diabetes Mellitus, Type 2 - economics | Health Benefit Plans, Employee - organization & administration | Male | Cost Sharing - economics | Angiotensin Receptor Antagonists - economics | Angiotensin-Converting Enzyme Inhibitors - economics | Metformin - economics | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Drug Costs - statistics & numerical data | Adult | Female | Imidazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Health Benefit Plans, Employee - economics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | Imidazoles - economics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Rosuvastatin Calcium - economics | Tetrazoles - therapeutic use | Aged | Disease Management | Diabetes Mellitus, Type 2 - drug therapy | Angiotensin Receptor Antagonists - therapeutic use | Health insurance | Metformin | Statins | Medical care, Cost of | Health care | Drugs | Diabetes mellitus | Employees | Disease management | Management | Disease control | Adhesion | Patient compliance | Employers | Diabetes | Original Research
Journal Article
Arquivos Brasileiros de Cardiologia, ISSN 0066-782X, 2015, Volume 104, Issue 1, pp. 32 - 43
Background: Statins have proven efficacy in the reduction of cardiovascular events, but the financial impact of its widespread use can be substantial.... 
Cost-benefit analysis | Prevention | Hydroxymethylglutaryl-CoA reductase inhibitors | Unified health system | Cardiovascular diseases | Cardiovascular Diseases | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | CHOLESTEROL | RISK | ISCHEMIC-HEART-DISEASE | ATORVASTATIN | Unified Health System | THERAPY | OLDER PATIENTS | Cost-Benefit Analysis | CARDIOVASCULAR-DISEASE | PRAVASTATIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors | ROSUVASTATIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Fluorobenzenes - economics | Male | Simvastatin - economics | Fluorobenzenes - administration & dosage | Models, Economic | Pyrroles - administration & dosage | Aged, 80 and over | Brazil | Heptanoic Acids - administration & dosage | Female | Pyrroles - economics | Cardiovascular Diseases - economics | Heptanoic Acids - economics | Primary Prevention - economics | Risk Assessment | Pyrimidines - administration & dosage | Simvastatin - administration & dosage | National Health Programs - economics | Risk Factors | Rosuvastatin Calcium | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | Pyrimidines - economics | Atorvastatin Calcium | Secondary Prevention - economics | Sulfonamides - economics | Aged | Sulfonamides - administration & dosage | Original | Redutases | Doenças Cardiovasculares | Prevenção | Sistema Único de Saúde | Inibidores da Hidroximetilglutaril-Co | Análise de Custo-Benefício
Journal Article
Medical Care, ISSN 0025-7079, 9/2010, Volume 48, Issue 9, pp. 761 - 766
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2016, Volume 11, Issue 7, p. e0158608
Purpose To examine HMG-CoA reductase inhibitor (statin) drug dispensing patterns to Nova Scotia Seniors' Pharmacare program (NSSPP) beneficiaries over a... 
C-REACTIVE PROTEIN | THERAPY | CHOLESTEROL | MULTIDISCIPLINARY SCIENCES | CARDIOVASCULAR-DISEASE | JUPITER TRIAL | PEOPLE | HEALTH | RISK-ASSESSMENT | PRIMARY PREVENTION | ROSUVASTATIN | Simvastatin - therapeutic use | Rosuvastatin Calcium - therapeutic use | Humans | Male | Lovastatin - supply & distribution | Atorvastatin Calcium - supply & distribution | Indoles - supply & distribution | Fatty Acids, Monounsaturated - therapeutic use | Aged, 80 and over | Female | Prescription Drugs - supply & distribution | Retrospective Studies | Pravastatin - therapeutic use | Atorvastatin Calcium - therapeutic use | Lovastatin - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - supply & distribution | Interrupted Time Series Analysis | Clinical Trials as Topic | Hypolipidemic Agents - supply & distribution | Simvastatin - supply & distribution | Health Knowledge, Attitudes, Practice | Pravastatin - supply & distribution | Prescription Drugs - therapeutic use | Nova Scotia | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Indoles - therapeutic use | Aged | Hypolipidemic Agents - therapeutic use | Fatty Acids, Monounsaturated - supply & distribution | Rosuvastatin Calcium - supply & distribution | Economic aspects | Aged patients | Care and treatment | Dosage and administration | Laws, regulations and rules | Statins | Availability | Time series analysis | Simvastatin | Time series | Dispensing | Data processing | Lovastatin | Cardiovascular disease | Insurance coverage | Pravastatin | Confidence intervals | Studies | Prescription drugs | Fluvastatin | Pharmacy | Atorvastatin | Population | Hydroxymethylglutaryl-CoA reductase | Trends | Pharmaceutical industry
Journal Article
European Journal of Preventive Cardiology, ISSN 2047-4873, 6/2012, Volume 19, Issue 3, pp. 474 - 483
Background: While evidence shows high-dose statins reduce cardiovascular events compared with moderate doses in individuals with acute coronary syndrome (ACS),... 
cost-effectiveness | economic evaluation | statin | Acute coronary syndrome | POPULATION | TRIALS | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | ATORVASTATIN | STATIN THERAPY | DISEASE | ROSUVASTATIN | BENEFITS | Drug Costs | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Markov Chains | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Drugs, Generic - economics | Fluorobenzenes - economics | Simvastatin - economics | Fluorobenzenes - administration & dosage | Models, Economic | Quality Indicators, Health Care - economics | Clinical Trials, Phase III as Topic | Drug Prescriptions - economics | Time Factors | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Pyrroles - economics | Cardiovascular Diseases - economics | Quality-Adjusted Life Years | Heptanoic Acids - economics | Pyrimidines - administration & dosage | Simvastatin - administration & dosage | Drugs, Generic - administration & dosage | Rosuvastatin Calcium | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | Treatment Outcome | Pyrimidines - economics | Randomized Controlled Trials as Topic | Atorvastatin Calcium | Medication Adherence | Secondary Prevention - economics | Cost-Benefit Analysis | Sulfonamides - economics | Bayes Theorem | Sulfonamides - administration & dosage
Journal Article
Journal Article
Journal of Medical Economics, ISSN 1369-6998, 7/2013, Volume 16, Issue 7, pp. 907 - 916
Journal Article